Anglia Ruskin University

File(s) under permanent embargo

COOL AMI EU pilot trial: a multicentre, prospective, randomised controlled trial to assess cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction

journal contribution
posted on 2023-09-01, 14:14 authored by Marko Noc, David Erlinge, Aleksandar Neskovic, Srdjan Kafedzic, Béla Merkely, Endre Zima, Misa Fister, Milovan Petrović, Milenko Čanković, Gábor Veress, Peep Laanmets, Teele Pern, Vladan Vukcevic, Vladimir Dedovic, Beata Średniawa, Andrzej Świątkowski, Thomas R. Keeble, John R. Davies, Alexandra-Maria Warenits, Göran Olivecrona, Jan Peruga, Michal Ciszewski, Ivan Horvath, Istvan Edes, Gergely Nagy, Daniel Aradi, Michael Holzer
Aims: We aimed to investigate the rapid induction of therapeutic hypothermia using the ZOLL Proteus Intravascular Temperature Management System in patients with anterior ST-elevation myocardial infarction (STEMI) without cardiac arrest. Methods and results: A total of 50 patients were randomised; 22 patients (88%; 95% confidence interval [CI]: 69-97%) in the hypothermia group and 23 patients (92%; 95% CI: 74-99) in the control group completed cardiac magnetic resonance imaging at four to six days and 30-day follow-up. Intravascular temperature at coronary guidewire crossing after 20.5 minutes of endovascular cooling decreased to 33.6°C (range 31.9-35.5°C). There was a 17-minute (95% CI: 4.6-29.8 min) cooling-related delay to reperfusion. In “per protocol” analysis, median infarct size/left ventricular mass was 16.7% in the hypothermia group versus 23.8% in the control group (absolute reduction 7.1%, relative reduction 30%; p=0.31) and median left ventricular ejection fraction (LVEF) was 42% in the hypothermia group and 40% in the control group (absolute reduction 2.4%, relative reduction 6%; p=0.36). Except for self-terminating paroxysmal atrial fibrillation (32% versus 8%; p=0.074), there was no excess of adverse events in the hypothermia group. Conclusions: We rapidly and safely cooled patients with anterior STEMI to 33.6°C at the time of coronary guidewire crossing. This is ≥1.1°C lower than in previous cooling studies. Except for self-terminating atrial fibrillation, there was no excess of adverse events and no clinically important cooling-related delay to reperfusion. A statistically non-significant numerical 7.1% absolute and 30% relative reduction in infarct size warrants a pivotal trial powered for efficacy. Identifier: NCT02509832



  • Yes



Issue number


Page range


Publication title





Europa Group

File version

  • Other


  • eng

Legacy posted date


Legacy Faculty/School/Department

ARCHIVED Faculty of Medical Science (until September 2018)

Usage metrics

    ARU Outputs


    No categories selected